AI and the Pharmaceutical Industry — 2026-11-04 (Wed)

Overview

Only four items were reported today. Two involved amounts: South Korea's build-out of a supercomputer for AI drug discovery ($274mn) and nPhase's fundraising ($30M). On the pharmaceutical company side, the main item is Merck's partnership with Variational AI to apply generative AI to drug discovery. Tempus AI's shares rose more than 10% after it reported an adjusted profit.

By Category

In drug discovery, the money is coming from two different kinds of players. South Korea is building national-scale computing infrastructure, while Merck is bringing generative AI into its own discovery process through its collaboration with Variational AI. The former reads as up-front investment in computing resources; the latter reads as a partnership-type adoption that uses an external generative model.

In enterprise AI infrastructure and governance, nPhase raised funds to expand its AI-native clinical data infrastructure (Clinical Data Fabrics) and agentic workflows. Tempus AI's shares rose on its first adjusted profit and an expanded partnership, which suggests the market is reacting to the monetization of AI infrastructure businesses. The headline does not reveal who the partner is.

Reading the Investment Map

The $274mn (South Korea's supercomputer) is a headline investment figure and shows capital going to the hardware side, namely computing infrastructure. The $30M (nPhase) is a funding amount and shows capital entering the software and data layer, namely clinical data infrastructure and agentic workflows. No amount is given for the Merck–Variational AI partnership, so its scale is unknown. The rise in Tempus AI's share price is a market reaction, not an investment amount.

What to Watch

Whether the target programs and terms of the Merck–Variational AI partnership are disclosed. 2. Who Tempus AI's expanded partners are and what the partnership covers, and whether the profit proves durable.